NYSE:BMYPharmaceuticals
How Investors May Respond To Bristol Myers (BMY) Mezigdomide Successor-2 Data And New Sotyktu Approval
In early March 2026, Bristol Myers Squibb reported positive interim Phase 3 SUCCESSOR-2 results for oral mezigdomide in relapsed or refractory multiple myeloma and secured U.S. FDA approval for Sotyktu (deucravacitinib) to treat adults with active psoriatic arthritis, expanding its presence in hematology and immunology.
Together, these developments highlight Bristol Myers Squibb’s depth in targeted protein degradation and TYK2 inhibition, underscoring how its research platforms can translate...